TCL-484 Treatment Patterns and Their Results Among a Cohort of Patients With T-Cell Lymphomas in the Russian Federation

• Published in: Clinical lymphoma, myeloma and leukemia Vol. 24; pp. S525 - S526
• Main Authors: Gorenkova, Liliya, Mangasarova, Yana, Kovrigina, Alla, Julhakyan, Hunan, Zvonkov, Evgeny
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01-09-2024
• Subjects: allogenic transplantation; auto-HSCT; maintenance therapy; T-cell lymphoma; TCL; treatment; treatment; maintenance therapy; auto-HSCT; TCL; T-cell lymphoma; allogenic transplantation
• ISSN: 2152-2650
• DOI: 10.1016/S2152-2650(24)01620-3

Peripheral T-cell lymphomas (PTCLs) are a rare group of aggressive lymphoproliferative diseases with unfavorable prognosis. Using personalized approaches, depending on the nosological form of PTCL, it is possible to obtain better antitumor response results; however, these studies are limited to a small number of patients.
We have accumulated our own 12-year experience with a large cohort of patients (724 patients with T-cell lymphomas, of which, 184 were classified as PTCLs), analyzed the results of treatment, and outlined therapeutic algorithms for each nosological form.
In the overall group, 3-year OS and PFS were 76% and 70%. High-dose chemotherapy (HDC) according to the NHL BFM-90 program in the treatment of anaplastic large-cell lymphoma (ALCL) allows the achievement of 10-year OS and EFS of 87% and 84%, respectively. However, according to an interim randomized study of the comparative effectiveness of HDC and CHOEP, the latter is not inferior in effectiveness: 5-year OS and RFS were 93% and 88%. Patients with enteropathy-associated T-cell lymphoma were treated with the NHL-BFM modified program (LB-M-04 in Russian register) followed by auto-HSCT as first-line therapy: 5-year OS and PFS were 79% and 74%. The positive role of maintenance therapy of angioimmunoblastic T-cell lymphoma (AITL) has been shown: 5-year OS and EFS in the presence of it were 75% and 49% vs 41% and 20% in the absence of it. The role of auto-HSCT in all PTCL was assessed: 5-year OS and EFS were 82% and 58% compared with 67% and 49% without auto-HSCT. Allogeneic bone marrow transplantation (allo-HCT) demonstrated the success of this treatment option - 9 of 11 patients are alive in remission from the disease.
Analysis of our own data shows a higher effectiveness of personalized therapy for some forms of PTCL, the validity of the option of maintenance therapy for AITL, and the lack of superiority of HDC over CHOEP in ALCL and confirms the need for the use of auto-HSCT and allo-HCT in the treatment of PTCL.